primaquine has been researched along with Cytomegalic Inclusion Disease in 2 studies
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primaquine group had lower 90-day mortality rate (45." | 1.72 | Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure. ( Cao, G; Liu, A; Liu, X; Sun, R; Yang, J; Zhu, H, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, A | 1 |
| Sun, R | 1 |
| Cao, G | 1 |
| Liu, X | 1 |
| Zhu, H | 1 |
| Yang, J | 1 |
2 other studies available for primaquine and Cytomegalic Inclusion Disease
| Article | Year |
|---|---|
Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.
Topics: Bacteremia; Clindamycin; Coinfection; Cytomegalovirus Infections; Humans; Pneumocystis carinii; Pneu | 2022 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |